Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) Infection.

Jeffrey M Jacobson David M Zahrieh Carrie A Strand Marcia Roxana Cruz-Correa Surakit Pungpapong Lewis Rowland Roberts Sumithra J Mandrekar Luz Maria Rodriguez Jean Boyer Idania Marrero Kimberly A Kraynyak Matthew P Morrow Albert J Sylvester Jan M Pawlicki Elisabeth Gillespie Eduardo Barranco Ellen Richmond Asad Umar David B Weiner Paul J Limburgnull null

Published in: Cancer prevention research (Philadelphia, Pa.) (2023)

The administration of IL12 DNA along with a hepatitis C viral antigen DNA vaccine enhanced the HCV-specific immune responses induced by the vaccine in individuals with chronic hepatitis C, an important cause of hepatocellular carcinoma. IL12 could be an effective adjuvant in vaccines targeting HCV and other oncogenic viruses.

Keyphrases

hepatitis c virus
circulating tumor
human immunodeficiency virus
cell free
single molecule
immune response
early stage
study protocol
transcription factor
randomized controlled trial
toll like receptor
liver fibrosis
inflammatory response
open label
genetic diversity